Research programme: restenosis therapies - NitroMed

Drug Profile

Research programme: restenosis therapies - NitroMed

Latest Information Update: 22 Aug 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boston Scientific Corporation; NitroMed
  • Developer NitroMed
  • Class
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Coronary artery restenosis

Most Recent Events

  • 31 Dec 2005 NitroMed and Boston Scientific have completed their collaboration on nitric oxide coated stents
  • 31 Dec 2003 Nitromed and Boston Scientific have extended an agreement to co-promote and co-develop nitric oxide coated stents worldwide
  • 30 Nov 2001 Preclinical trials in Coronary artery restenosis in USA (Implant)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top